PURELL® 5192-04 FMX-12™ Hand Sanitizer, 1200 mL Nominal, Dispenser Refill Package, Foam Form, Fruity/Odorless Odor/Scent, Clear/Colorless/Yellow

13751923 MFG #: 5192-04
$0.00 / Case of 4
In Stock
  • Series: FMX-12™
  • Nominal Capacity: 1200
  • Package Type: Dispenser Refill
  • Packing Type: Dispenser Refill
  • Form: Foam
  • Color: Clear/Colorless/Yellow
  • Odor/Scent: Fruity/Odorless
  • Composition: Ethanol, Propan-2-ol
  • pH Range: 5.5 to 9
  • Flash Point: 25.5
PURELL® Hand Sanitizer, Series: FMX-12™, 1200 mL Nominal Capacity, Dispenser Refill, Foam, Clear/Colorless/Yellow, Fruity/Odorless, Composition: Ethanol, Propan-2-ol, 5.5 to 9 pH, 25.5 deg C Flash
QTY
  • Luxurious foam
  • Kills more than 99.9
  • Kills more than 99.99% of most common germs that may cause illness
  • Outperforms other hand sanitizers ounce for ounce
  • Outperforms other hand sanitizers ounce-for-ounce
  • Clinically proven to maintain skin health
  • Clinically-proven to maintain skin health
  • America's #1 instant hand sanitizer
  • America's #1 instant
  • Removable pump for easier recycling
  • Removable pump for e
  • SANITARY SEALED™ refill helps prevent contamination
  • SANITARY SEALED™ ref
  • Kills 99.99% of most common germs that may cause illness
  • Disclaimer
  • Disclaimer
  • Disclaimer
Luxurious foam
• Kills more than 99.99% of most common germs that may cause illness
Kills more than 99.99% of most common germs that may cause illness
Outperforms other hand sanitizers ounce for ounce
Outperforms other hand sanitizers ounce-for-ounce
Clinically proven to maintain skin health
Clinically-proven to maintain skin health
America's #1 instant hand sanitizer
• America's #1 instant hand sanitizer
Removable pump for easier recycling
• Removable pump for easier recycling
SANITARY SEALED™ refill helps prevent contamination
• SANITARY SEALED™ refill helps prevent contamination
Kills 99.99% of most common germs that may cause illness
Disclaimer_1: Healthcare personnel handwash Study #110103-101, April 5, 2011, and #100907-101, Jan 6th, 2011, BioScience Laboratories, Bozeman, MT
Disclaimer_2: Clinical field study #2011-F10232, April 2011
Disclaimer_3: IRI 52wks ending 9/8/13 with HPIS sales data from May 2013